Arvinas and Pfizer Announce Positive Topline Results from Phase …
3 days ago · NEW HAVEN, Conn. and NEW YORK, March 11, 2025 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast ...
Arvinas and Pfizer Announce Positive Topline Results from Phase …
3 days ago · Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas and Pfizer will successfully perform their respective obligations under the collaboration between ...
Arvinas and Pfizer Announce Global Collaboration to Develop …
Jul 22, 2021 · NEW HAVEN, Conn. and NEW YORK – July 22, 2021 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader.
Arvinas and Pfizer Announce Positive Topline Results from Phase …
3 days ago · NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 ...
Arvinas and Pfizer Announce Positive Topline Results from
3 days ago · --Arvinas, Inc. and Pfizer Inc. today announced positive topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen ...
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast …
NEW YORK, February 6, 2024 - Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of vepdegestrant (ARV-471) for monotherapy in the treatment of adults with estrogen receptor (ER) positive/human growth epidermal growth ...
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast …
Feb 6, 2024 · In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will equally share worldwide development costs, commercialization expenses, and profits.
Arvinas, Pfizer announce VERITAC-2 achieved primary endpoint …
3 days ago · Arvinas and Pfizer announced topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human ...
Arvinas and Pfizer Announce Positive Phase 3 VERITAC-2 Trial
3 days ago · Arvinas, Inc. and Pfizer Inc. announced positive results from the Phase 3 VERITAC-2 clinical trial, which evaluated vepdegestrant, an investigational oral PROTAC ER degrader, in adults with ...
Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for …
3 days ago · Pfizer and Arvinas’ investigational PRTOAC degrader vepdegestrant can improve progression-free survival in breast cancer patients—but only in those carrying a specific genetic mutation.. The mixed bag comes from a topline readout of the Phase III VERITAC-2 trial released on Tuesday, comparing vepdegestrant against AstraZeneca’s Faslodex.
- Some results have been removed